Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Bal

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the dataSusan Bal
The Lancet. Haematology|March 16, 2025
Monumen-TAL progress in the treatment of relapsed multiple myelomaSusan Bal
Hematology. American Society of Hematology. Education Program|December 10, 2021
AL amyloidosis: untangling new therapiesSusan Bal, Heather Landau
Blood Cancer Discovery|November 26, 2024
Total (Immuno)Therapy: Version 2.0Susan Bal, Luciano J Costa
The Lancet. Haematology|May 28, 2021
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapySusan Bal, Luciano J Costa
Hematology/Oncology Clinics of North America|October 25, 2020
Solid Organ TransplantationSusan Bal, Heather J Landau
Cancer|September 23, 2020
Age is just a number, the wrong numberSusan Bal, Luciano J Costa
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Best practices for the assessment of measurable residual disease (MRD) in multiple myelomaSusan Bal, Luciano J Costa
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observationsLuciano J Costa, Susan Bal
British Journal of Haematology|April 8, 2021
Autologous stem cell transplantation in the age of ANDROMEDASusan Bal, Morie A Gertz
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the dataSusan Bal
The Lancet. Haematology|March 16, 2025
Monumen-TAL progress in the treatment of relapsed multiple myelomaSusan Bal
Hematology. American Society of Hematology. Education Program|December 10, 2021
AL amyloidosis: untangling new therapiesSusan Bal, Heather Landau
Blood Cancer Discovery|November 26, 2024
Total (Immuno)Therapy: Version 2.0Susan Bal, Luciano J Costa
The Lancet. Haematology|May 28, 2021
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapySusan Bal, Luciano J Costa
Hematology/Oncology Clinics of North America|October 25, 2020
Solid Organ TransplantationSusan Bal, Heather J Landau
Cancer|September 23, 2020
Age is just a number, the wrong numberSusan Bal, Luciano J Costa
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Best practices for the assessment of measurable residual disease (MRD) in multiple myelomaSusan Bal, Luciano J Costa
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observationsLuciano J Costa, Susan Bal
British Journal of Haematology|April 8, 2021
Autologous stem cell transplantation in the age of ANDROMEDASusan Bal, Morie A Gertz
Pageof 7